Bookmark
Forward
QuickView for Benztropine (compound)
PubChem
| Name: | Benztropine |
|---|---|
| PubChem Compound ID: | 1201549 |
| Description: | A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine. |
| Molecular formula: | C21H25NO |
| Molecular weight: | 307.429 g/mol |
| Synonyms: |
Benztropine; Benztropine Benzatropine
|
DrugBank
Identification
| Name: | Benztropine |
|---|---|
| Name (isomeric): | DB00245 |
| Drug Type: | small molecule |
| Description: | A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine. |
| Synonyms: |
Benzatropinum [INN-Latin]; Benztropine Mesylate; Benzatropine mesilate; Tropine Benzohydryl Ether; Benztropinum; Benzatropina [INN-Spanish]; Benzatropine
|
| Brand: | Cogentinol, PMS Benztropine, Cogentin, Akitan, Cobrentin, Apo-Benztropine |
| Category: | Muscarinic Antagonists, Parasympatholytics, Antidyskinetics, Antiparkinson Agents |
| CAS number: | 86-13-5 |
Pharmacology
| Indication: | For use as an adjunct in the therapy of all forms of parkinsonism and also for use in the control of extrapyramidal disorders due to neuroleptic drugs. |
|---|---|
| Pharmacology: |
Benztropine is an anticholinergic used in the symptomatic treatment of all etiologic groups of parkinsonism and drug-induced extrapyramidal reactions (except tardive dyskinesia). Benztropine possesses both anticholinergic and antihistaminic effects, although only the former has been established as therapeutically significant in the management of pa...
show more » |
| Mechanism of Action: |
Benztropine is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Benztropine partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinson's disease. It is also thought to...
show more » |
| Absorption: | Onset of action is 1-2 hours following oral administration. The onset of action is within minutes when administered by IM or IV injection. |
| Protein binding: | ~95% to serum proteins |
| Toxicity: | Signs of overdose include confusion, nervousness, listlessness, hallucinations, dizziness; muscle weakness, ataxia, dry mouth, mydriasis, blurred vision, palpitations, tachycardia, elevated blood pressure, nausea, vomiting, dysuria, numbness of fingers, headache, delirium, coma, shock, convulsions, respiratory arrest, anhidrosis, hyperthermia, glaucoma, and constipation. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
